Jump to section
About this journal
Aims and scope
Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology.
Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field.
In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.
Articles published in Therapeutic Delivery cover key areas such as:
- Delivery of small molecule drugs, vaccines, radionuclides, proteins, peptides, genes, siRNA, nucleotides, stem cells and diagnostic probes
- Targeting at the molecular, cellular, organ and systemic levels
- Techniques for crossing biological barriers
- Methods for enhancement of pharmacokinetic profiles
- Absorption/distribution pharmacokinetics in relation to drug delivery
- Biodynamic and bioresponsive delivery
- Stimuli triggered delivery
- Parenteral delivery
- Nanotechnology
- Personalized therapeutic delivery
- Drug release mechanisms
- Combination products and delivery devices
- Design and characterization of dosage forms
- Drug formulation research and development
- Physiochemical and biological properties of drugs
- Intellectual property, competitor intelligence and partnering news
- Cost / benefit analyses
- In vitro, in vivo and in silico delivery studies
- Emerging technologies
The journal welcomes unsolicited article proposals.
Journal metrics
Citation metrics
- 3.0 (2023) Impact Factor
- Q2 Impact Factor Best Quartile
- 3.7 (2023) 5 year IF
- 5.5 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.541 (2023) SNIP
- 0.455 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Senior Editor
Banga AK, Mercer University, Atlanta, GA, USA
Associate Editors
Chow MSS, Western University of Health Sciences, CA, USA
Dinh S, CutisPharma, Wilmington, MA, USA
Prud'homme RK, Princeton University, NJ, USA
Tendler S, University of York, UK
Wang G, China Pharmaceutical University, China
International Editorial Advisory Board
Al-Salami H,Curtin University, Perth, Australia
Arora M, University of Alamaba, AL, USA
Bakshi P,GlaxoSmithKline, VA, USA
Bhattacharjee H, The University of Tennessee Health Science Center, TN, USA
Das S, Bulter University, College of Pharmacy & Health Sciences, IN, USA
Dash AK, Creighton University, NE, USA
Destache C, Creighton University, NE, USA
Gabathuler R, Cydweli Consultants Inc., Quebec, Canada
Greish K,Arabian Gulf University, Kingdom of Bahrain
Goswami T, Senior Manager, Amneal Pharmaceuticals, NJ, USA
Heng P, National University of Singapore, Singapore
Ho P, National University of Singapore, Singapore
Ho RJY, University of Washington, USA
Jia L, National Institutes of Health (NIH), Bethesda, USA
Jelvehgari M, University of Tabriz, Tabriz, Iran
Jones DS, The Queen's University of Belfast, Medical Biology Centre, School of Pharmacy, Northern Ireland, UK
Khan Ghilzai N, School of Pharmacy, West Coast University, CA, USA
Khang G, Chonbuk National University, Korea
Lee BJ, Ajou University, Republic of Korea
Li S,Queen's University Belfast, Northern Ireland, UK
Matsumura Y, National Cancer Center Hospital East, Japan
Mandal S, University of Nebraska-Lincoln, NE, USA
McCartney F, University College Dublin, Republic of Ireland
Medintz I, U.S. Naval Research Laboratory Code 6900, USA
Miller AD, Imperial College Genetic Therapies Centre, UK
Mohammed AR, Aston University, UK
Moridani M, Medical College of Wisconsin, USA
Müllertz A, University of Copenhagen, Denmark
Nadia Passerini,University of Bologna, Italy
Rautio J, University of Eastern Finland, Finland
Rees G, Genesis Oral, UK
Reis C, Universidade Lusófona de Humanidades e Tecnologias, Portugal
Rosenmayr-Templeton L, Tower Pharma Consulting, Austria
Shameem M, Regeneron Pharmaceuticals, Tarrytown, NY, USA
Stinchcomb AL, University of Kentucky and AllTranz Inc, Lexington, KY, USA
Sun D, The University of Michigan, MI, USA
Tambuwala M, Ulster University, Northern Ireland, UK
Tiwary AK, Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, India
Uchegbu IF, University of London, UK
Vig B, Bristol-Myers Squibb, USA
Younes HM, Qatar University, Qatar
Zinzalla G, Karolinska Institute, Sweden
Open access
Therapeutic Delivery is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
12 issues per year
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors